Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects

被引:7
|
作者
Nuglozeh, Edem [1 ,5 ]
Fazaludeen, Mohammad Feroze [3 ]
Hasona, Nabil [1 ,2 ]
Malm, Tarja [3 ]
Mayor, Luisito B. [4 ]
Al-Hazmi, Awdah [1 ]
Ashankyty, Ibraheem [4 ]
机构
[1] Univ Hail, Coll Med, Dept Biochem, Hail, Saudi Arabia
[2] Beni Suef Univ, Fac Sci, Biochem Div, Chem Dept, Bani Suwayf, Egypt
[3] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Neulaniementie 2, Kuopio 70211, Finland
[4] Univ Hail, Coll Appl Med Sci, Dept Clin Diagnost, Hail, Saudi Arabia
[5] Univ Hail, Coll Med, Dept Biochem & Mol Biol, Hail, Saudi Arabia
关键词
PCSK9; Single-nucleotide polymorphism; Hypercholesterolemia; Diabetes; Eucholesterolemia; LOW-DENSITY-LIPOPROTEIN; PLASMA LDL-CHOLESTEROL; GENETIC-VARIANTS; CORRELATE; RISK;
D O I
10.1007/s12291-018-0763-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-synonymous single-nucleotide polymorphism (SNPs) in the gene for proprotein convertase subtilisin/kexin type 9 (PCSK9) can influence cholesterol and glucose metabolism, leading to increased risk of cardiovascular disease and diabetes. To determine the frequency of four common PCSK9 SNPs, L10Ins, A56V, I474V, and E670G, in a population sample (n=98) of the Hail region of Kingdom of Saudi Arabia. Blood was collected from participants; serum cholesterol, blood glucose and glycated hemoglobin were determined; genomic DNA was extracted and PCR amplicons from SNP-containing PCSK9 exons were subjected to Sanger sequencing. Out of 98 participants. 10 (10.20%) carried none of the SNPs, 2 (2.04%) the L10ins/A56V linked SNPs, 35 (35.71%) the I474V SNP, 22 (22.45%) both the I474V and E670G SNPs, and 29 (29.59%) the E670G SNP. Of the 30 eucholesterolemic diabetics patients, 11 (36.66%) carried the I474V SNP, 10 (33.33%) the E679G SNP and 6 (20%) the I474V/E679G. SNPs. Of 63 diabetic patients, 26 (41.26%) carry I474V SNP and 22 (34.92%) carry E670G SNP. Our data demonstrated that the I474V and E670G PCSK9 variants are very frequent in the Hail region of Saudi Arabia and are found at even higher frequency among diabetics. Further investigations are needed to determine whether these variations or another variant segregating with them can explain its apparent association with diabetes in this population.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 50 条
  • [41] Characterization of LDLR rs5925 and PCSK9 rs505151 genetic variants frequencies in healthy subjects from northern Chile: Influence on plasma lipid levels
    Rojas, Claudio
    Ramirez, Hugo
    Salazar, Luis A.
    Kalergis, Alexis M.
    Galvez, Anita S.
    Escobar-Vera, Jorge
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (09)
  • [42] Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China
    Han, Deng-feng
    Ma, Jian-hua
    Hao, Chen-guang
    Tuerxun, Tuerhong
    Du, Lei
    Zhang, Xiao-ning
    NEURAL REGENERATION RESEARCH, 2017, 12 (08) : 1315 - 1321
  • [43] Bile acid synthesis precursors in subjects with genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and carotid atherosclerosis
    Baila-Rueda, L.
    Cenarro, A.
    Lamiquiz-Moneo, I.
    Mateo-Gallego, R.
    Bea, A. M.
    Perez-Calahorra, S.
    Marco-Benedi, V.
    Civeira, F.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 169 : 226 - 233
  • [44] Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
    Ridker, Paul M.
    Rose, Lynda M.
    Kastelein, John J. P.
    Santos, Raul D.
    Wei, Caimiao
    Revkin, James
    Yunis, Carla
    Tardif, Jean-Claude
    Shear, Charles L.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 958 - 965
  • [45] Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk - Primary Results From the Phase 2 YUKAWA Study
    Hirayama, Atsushi
    Honarpour, Narimon
    Yoshida, Masayuki
    Yamashita, Shizuya
    Huang, Fannie
    Wasserman, Scott M.
    Teramoto, Tamio
    CIRCULATION JOURNAL, 2014, 78 (05) : 1073 - U86
  • [46] Upregulation of PCSK9, rho kinase and cardiac troponin by Eucalyptus globulus leaf extract improves fructose-streptozotocin-induced diabetic cardiac dysfunction in rats
    Akinmoladun, Afolabi C.
    Bello, Morenikejimi
    Ibukun, Emmanuel Oluwafemi
    ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 2023, 129 (06) : 1219 - 1228
  • [47] Association between plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and lipids with rs7903146 polymorphisms of the TCF7L2 gene in diabetic patients
    Rohollah Yousefi
    Narges Mohammadtaghvaei
    Mehrnoosh Zakerkish
    Hamid Yaghooti
    Ali Karimi Akhormeh
    Ramin Tavakoli
    International Journal of Diabetes in Developing Countries, 2019, 39 : 380 - 386
  • [48] E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China
    He, Xi-Min
    Chen, Lin
    Wang, Tian-Song
    Zhang, Yun-Bo
    Luo, Jiang-Bin
    Peng, Xu-Xia
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2016, 9 (02) : 169 - 174
  • [49] A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
    Lunven, Catherine
    Paehler, Tobias
    Poitiers, Franck
    Brunet, Aurelie
    Rey, Jacques
    Hanotin, Corinne
    Sasiela, William J.
    CARDIOVASCULAR THERAPEUTICS, 2014, 32 (06) : 297 - 301
  • [50] Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting
    Scicali, Roberto
    Di Pino, Antonino
    Ferrara, Viviana
    Rabuazzo, Agata Maria
    Purrello, Francesco
    Piro, Salvatore
    ACTA DIABETOLOGICA, 2021, 58 (07) : 949 - 957